This work provides significant insights on the (epi)genetic mechanisms underlying WNT6 activation in highly aggressive GBMs, which may potentially influence GBM patients’ management by aiding treatment decisions and prognostic stratifications, while also opening new opportunities to identify or develop potentially more effective therapies for these highly resistant tumors. This evidence concerns the gene WNT6 and glioblastoma.